[Clinical pharmacokinetics of viloxazine chlorhydrate. Practical implications]. 1989

S Bouquet, and B Vandel, and S Guibert, and J Lavoisy
Laboratoire Pharmacocinétique, CHRU La Milétrie, Poitiers.

Pharmacokinetic data of an antidepressant agent: Apparent half-life (T1/2 elim), time of peak plasma concentration (Tmax), bioavailability, have a major contribution to determine optimal dosage in accordance with a low modification of steady-state levels. Viloxazine is a second generation antidepressant drug with a short apparent half-life (T1/2 elim: 2 to 5 h (3.4 h), which requires once a day 3 h i.v. infusion or three intakes of 100 mg oral standard formulation. The recent development of a new 300 mg slow-release form seems justified by a best compliance. Pharmacokinetic properties [Tmax = 3 to 9 h (5.2 h), T1/2 term = 6 to 7 h], suggest once a day dosage without risk of accumulation in chronic treatment. The relationships between plasma levels and the clinical improvement were not clear in literature. The recent therapeutic use of a 300 mg slow-release tablet has not permitted to change precedent findings.

UI MeSH Term Description Entries
D007263 Infusions, Parenteral The administration of liquid medication, nutrient, or other fluid through some other route than the alimentary canal, usually over minutes or hours, either by gravity flow or often by infusion pumping. Intra-Abdominal Infusions,Intraperitoneal Infusions,Parenteral Infusions,Peritoneal Infusions,Infusion, Intra-Abdominal,Infusion, Intraperitoneal,Infusion, Parenteral,Infusion, Peritoneal,Infusions, Intra-Abdominal,Infusions, Intraperitoneal,Infusions, Peritoneal,Intra Abdominal Infusions,Intra-Abdominal Infusion,Intraperitoneal Infusion,Parenteral Infusion,Peritoneal Infusion
D009025 Morpholines Tetrahydro-1,4-Oxazines,Tetrahydro 1,4 Oxazines
D003692 Delayed-Action Preparations Dosage forms of a drug that act over a period of time by controlled-release processes or technology. Controlled Release Formulation,Controlled-Release Formulation,Controlled-Release Preparation,Delayed-Action Preparation,Depot Preparation,Depot Preparations,Extended Release Formulation,Extended Release Preparation,Prolonged-Action Preparation,Prolonged-Action Preparations,Sustained Release Formulation,Sustained-Release Preparation,Sustained-Release Preparations,Timed-Release Preparation,Timed-Release Preparations,Controlled-Release Formulations,Controlled-Release Preparations,Extended Release Formulations,Extended Release Preparations,Slow Release Formulation,Sustained Release Formulations,Controlled Release Formulations,Controlled Release Preparation,Controlled Release Preparations,Delayed Action Preparation,Delayed Action Preparations,Formulation, Controlled Release,Formulations, Controlled Release,Prolonged Action Preparation,Release Formulation, Controlled,Release Formulations, Controlled,Sustained Release Preparation,Timed Release Preparation,Timed Release Preparations
D003866 Depressive Disorder An affective disorder manifested by either a dysphoric mood or loss of interest or pleasure in usual activities. The mood disturbance is prominent and relatively persistent. Depression, Endogenous,Depression, Neurotic,Depression, Unipolar,Depressive Syndrome,Melancholia,Neurosis, Depressive,Unipolar Depression,Depressions, Endogenous,Depressions, Neurotic,Depressions, Unipolar,Depressive Disorders,Depressive Neuroses,Depressive Neurosis,Depressive Syndromes,Disorder, Depressive,Disorders, Depressive,Endogenous Depression,Endogenous Depressions,Melancholias,Neuroses, Depressive,Neurotic Depression,Neurotic Depressions,Syndrome, Depressive,Syndromes, Depressive,Unipolar Depressions
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D014745 Viloxazine A morpholine derivative used as an antidepressant. It is similar in action to IMIPRAMINE. Emovit,ICI-58,834,Viloxazine Hydrochloride,Viloxazine Hydrochloride, (R)-Isomer,Viloxazine Hydrochloride, (S)-Isomer,Viloxazine Oxalate (1:1),Viloxazine, (+-)-Isomer,Viloxazine, (R)-Isomer,Viloxazine, (S)-Isomer,Vivalan,ICI58,834

Related Publications

S Bouquet, and B Vandel, and S Guibert, and J Lavoisy
January 1983, L'Encephale,
S Bouquet, and B Vandel, and S Guibert, and J Lavoisy
October 1991, Clinical pharmacokinetics,
S Bouquet, and B Vandel, and S Guibert, and J Lavoisy
January 1982, European journal of drug metabolism and pharmacokinetics,
S Bouquet, and B Vandel, and S Guibert, and J Lavoisy
February 1986, Nederlands tijdschrift voor geneeskunde,
S Bouquet, and B Vandel, and S Guibert, and J Lavoisy
March 1981, Pharmacopsychiatria,
S Bouquet, and B Vandel, and S Guibert, and J Lavoisy
June 1991, Clinical pharmacokinetics,
S Bouquet, and B Vandel, and S Guibert, and J Lavoisy
September 1961, Bruxelles medical,
S Bouquet, and B Vandel, and S Guibert, and J Lavoisy
October 1961, Bruxelles medical,
S Bouquet, and B Vandel, and S Guibert, and J Lavoisy
June 1977, The American journal of psychiatry,
S Bouquet, and B Vandel, and S Guibert, and J Lavoisy
March 1993, Clinical pharmacokinetics,
Copied contents to your clipboard!